Therapeutic drug monitoring in children with cancer

Not Applicable

• Conditions: Cancer

• Registration Number: ISRCTN10139334
• Lead Sponsor: ewcastle upon Tyne Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-10
• Last Update Posted: 20 November 2023
• Study Completion: 2029-06-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Age <18 years.
2. Confirmed diagnosis of cancer.
3. Patient receiving a ‘non-standard’ strategy of chemotherapy delivery (see below for examples of patient groups that fall into this category).*
4. Appropriate venous access.
5. Request from the treating clinician for therapeutic drug monitoring approach to treatment.
6. Willingness to participate and written informed parental/patient consent (signed and dated).

* Patients receiving non-standard chemotherapy dosing regimens will include the following groups: pre-term infants and neonates, anephric patients, patients receiving high dose myeloablative chemotherapy, patients undergoing chemoembolisation procedures, obese patients (BMI at or above the 95th percentile for children of the same age and sex).

Exclusion Criteria

Failure to meet the inclusion criteria.

Study & Design

• Study Type: Observational
• Study Design: Not specified